Abstract
ObjectivesSodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF and mortality among patients with cancer...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have